全文获取类型
收费全文 | 14894篇 |
免费 | 1368篇 |
国内免费 | 464篇 |
专业分类
耳鼻咽喉 | 623篇 |
儿科学 | 569篇 |
妇产科学 | 87篇 |
基础医学 | 1961篇 |
口腔科学 | 616篇 |
临床医学 | 1775篇 |
内科学 | 3826篇 |
皮肤病学 | 28篇 |
神经病学 | 321篇 |
特种医学 | 289篇 |
外国民族医学 | 2篇 |
外科学 | 2058篇 |
综合类 | 2380篇 |
现状与发展 | 2篇 |
预防医学 | 383篇 |
眼科学 | 61篇 |
药学 | 1155篇 |
6篇 | |
中国医学 | 472篇 |
肿瘤学 | 112篇 |
出版年
2024年 | 20篇 |
2023年 | 277篇 |
2022年 | 382篇 |
2021年 | 594篇 |
2020年 | 641篇 |
2019年 | 571篇 |
2018年 | 576篇 |
2017年 | 605篇 |
2016年 | 611篇 |
2015年 | 572篇 |
2014年 | 1032篇 |
2013年 | 1107篇 |
2012年 | 912篇 |
2011年 | 1051篇 |
2010年 | 829篇 |
2009年 | 840篇 |
2008年 | 847篇 |
2007年 | 868篇 |
2006年 | 712篇 |
2005年 | 643篇 |
2004年 | 499篇 |
2003年 | 404篇 |
2002年 | 353篇 |
2001年 | 288篇 |
2000年 | 198篇 |
1999年 | 202篇 |
1998年 | 159篇 |
1997年 | 165篇 |
1996年 | 123篇 |
1995年 | 92篇 |
1994年 | 74篇 |
1993年 | 71篇 |
1992年 | 55篇 |
1991年 | 48篇 |
1990年 | 35篇 |
1989年 | 39篇 |
1988年 | 31篇 |
1987年 | 20篇 |
1986年 | 22篇 |
1985年 | 49篇 |
1984年 | 19篇 |
1983年 | 21篇 |
1982年 | 17篇 |
1981年 | 11篇 |
1980年 | 10篇 |
1979年 | 8篇 |
1978年 | 5篇 |
1977年 | 8篇 |
1975年 | 4篇 |
1973年 | 2篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
1.
2.
3.
目的探讨经鼻间歇正压通气(NIPPV)在防治早产儿呼吸窘迫综合征(RDS)中的应用价值。方法选择2017年6月至2018年12月梧州市人民医院RDS早产儿90例,其中男性48例,女性42例;胎龄(29.03±0.58)周;出生体质量(996.91±98.52)g;病程(3.48±0.56)h;临床分级Ⅰ级58例,Ⅱ级32例;Apgar评分(6.85±1.06)分。依据随机数字表分为NIPPV组和持续气道正压通气(NCPAP)组,每组45例。NIPPV组给予NIPPV治疗,NCPAP组给予NCPAP治疗,若两组治疗后不能维持患儿生命体征则使用肺表面活性物质(PS)或行有创机械通气。结果NIPPV组和NCPAP组治疗12、24 h后和治疗结束时动脉血氧分压(PaO2)、氧合指数(OI)明显高于治疗前。NIPPV组治疗12、24 h后PaO2、OI明显高于NCPAP组,差异有统计学意义(P<0.05)。NIPPV组和NCPAP组治疗结束时PaO2、OI比较,差异无统计学意义(P>0.05);NIPPV组PS使用率(22.22%vs 44.44%)、有创通气率(17.78%vs 40.00%)、氧疗时间[(71.42±7.62)h vs(85.62±9.24)h]、有创通气时间[(46.78±5.32)h vs(55.27±6.14)h]、住院时间[(30.42±3.65)d vs(35.62±3.89)d]、并发症率(31.11%vs 53.33%)明显低于NCPAP组,差异有统计学意义(P<0.05)。结论NIPPV可有效改善RDS早产儿通气功能,有利于减少PS使用、有创通气及并发症,值得临床推广。 相似文献
4.
5.
目的:比较经鼻导管高流量吸氧(HFNC)与经鼻气道正压通气(nCPAP)在重症毛细支气管炎呼吸支持中的应用价值,为临床治疗方案的选择提供参考。方法:选取2016年12月至2018年12月我院儿科收治的重症毛细支气管炎患儿90例,采用随机数字表法分为观察组和对照组各45例。两组患儿入院后均给予常规综合治疗以保证呼吸道通畅,在此基础上观察组采用HFNC治疗,对照组采用nCPAP治疗,比较两组患儿治疗前和治疗24 h后呼吸频率、经皮血氧饱和度(TcSO2)、呼吸窘迫评分体系(CSS)评分、动脉血氧分压(PaO2)等呼吸相关指标及治疗前后临床症状体征改善情况。结果:两组患儿治疗24 h后呼吸频率、CSS评分均降低,且观察组降低程度更大,TcSO2、PaO2于治疗24 h后升高,观察组升高幅度较对照组明显;治疗后两组患儿咳嗽及肺部湿啰音、肺部炎症情况均改善,观察组症状体征消失时间早于对照组,差异均有统计学意义(P<0.05)。结论:重症毛细支气管炎患儿采用HFNC治疗可明显改善通气功能和临床症状,治疗效果优于nCPAP治疗,可扩大样本量进一步观察。 相似文献
6.
7.
Could non-HDL-cholesterol be a better marker of atherogenic dyslipidemia in obstructive sleep apnea?
《Sleep medicine》2021
Background/objectiveObstructive sleep apnea (OSA) is independently associated with dyslipidemia, a surrogate marker of atherosclerosis. Low-density lipoprotein (LDL)-cholesterol is accepted as a major independent risk factor for cardiovascular disease. However, non-high-density lipoprotein (HDL)-cholesterol is a better marker of atherogenic dyslipidemia and recommended as a target of lipid lowering therapy. We aimed to assess the prevalence of atherogenic dyslipidemia, and relationship between OSA severity and serum LDL-cholesterol and non-HDL cholesterol levels in OSA patients.MethodsWe retrospectively evaluated treatment naïve 2361 subjects admitted to the sleep laboratory of a university hospital for polysomnography. All subjects’ lipid profile including total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, and non-HDL-cholesterol were measured.ResultsOut of 2361 patients (mean age 49.6 ± 11.9 years; 68.9% male, apnea-hypopnea index 36.6 ± 28.4/h), 185 (7.8%) had no OSA and 2176 (92.2%) had OSA. Atherogenic dyslipidemia prevalence was high (57–66%) in OSA patients, and especially increased in severe OSA compared to other groups (p < 0.05). Though total and LDL-cholesterol did not differ between those with and without OSA, non-HDL-cholesterol (p = 0.020), and triglycerides (p = 0.001) were higher and HDL-cholesterol levels (p = 0.018) were lower in OSA patients than non-OSA. Non-HDL-cholesterol was significantly correlated with OSA severity (p < 0.001) and hypoxia parameters (p < 0.01), whereas LDL-cholesterol showed no correlation.ConclusionsAtherogenic dyslipidemia is highly prevalent and non-HDL-cholesterol levels are significantly increased, predominantly in severe OSA patients. Non-HDL-cholesterol but not LDL-cholesterol, is significantly correlated with OSA severity and hypoxia parameters. Therefore, it could be better to use non-HDL-cholesterol, which is a guideline recommended target of lipid therapy, as a marker of atherosclerotic cardiovascular risk in OSA patients. 相似文献
8.
9.
Christos Loizou Göran Laurell Andreas Arvidsson David Lindquist Karin Nylander Katarina Olofsson 《Acta oto-laryngologica》2015,135(10):1058-1064
Conclusion: Recurrent respiratory papillomatosis (RRP) patients with high surgical treatment frequency (≥ 1/year, HF) were significantly younger and had a more widespread laryngeal disease compared to a low frequency treated group (< 1 treatment/year, LF). This study confirms the existence of a clinical RRP group, not primarily related to HPV sub-type, but more care-intensive and in need of more vigilant follow-up. Objectives: RRP is associated with high morbidity due to its influence on breathing and voice. The purpose of this study was to characterize RRP patients in northern Sweden and investigate possible predictor factors affecting therapeutic needs. Method: Patients from the regional referral area (northern Sweden) were categorized for age, disease duration, juvenile or adult onset, profile of disease development, number of surgical sessions in relation to disease duration, laryngeal deposition of papilloma, gender, and HPV sub-types, in order to identify patients with increased need for frequent surgical treatment. Results: The median age of the RRP patients (n = 48) was 44.5 years; 34 (71%) were males and 14 (29%) females, most were infected with HPV 6. Patients with high surgical treatment frequency/year were significantly younger and showed more widespread papillomatous vegetation in the larynx, compared to the low frequency treated group. 相似文献
10.
Ewelina Kazimierczyk Andrzej Eljaszewicz Paula Zembko Ewa Tarasiuk Malgorzata Rusak Agnieszka Kulczynska-Przybik Marta Lukaszewicz-Zajac Karol Kaminski Barbara Mroczko Maciej Szmitkowski Milena Dabrowska Bozena Sobkowicz Marcin Moniuszko Agnieszka Tycinska 《Pharmacological reports : PR》2019,71(1):73-81